Ironwood receives NOA for patent expected to extend LINZESS patent protection Ironwood Pharmaceuticals (IRWD) announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent application covering methods of using LINZESS to treat patients with irritable bowel syndrome with constipation or chronic idiopathic constipation. The patent application, co-owned by Ironwood and Forest Laboratories (FRX), is expected to issue in mid-2014 and extend LINZESS patent protection into 2031. LINZESS is approved and marketed in the United States for the treatment of adult patients suffering from IBS-C or CIC. It is the first and only guanylate cyclase-C agonist approved by the FDA.
News For IRWD;FRX From The Last 14 Days
Check below for free stories on IRWD;FRX the last two weeks.